Cohance Lifesciences Limited
1,154words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
29.72%
Rs. Crore 5 Financial Snapshot Q1FY23 FY22 Growth in Revenue Growth in EBITDA Growth in PAT 29.72% 37.57% 40.04% 47.27% 68.83% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to In
37.57%
e 5 Financial Snapshot Q1FY23 FY22 Growth in Revenue Growth in EBITDA Growth in PAT 29.72% 37.57% 40.04% 47.27% 68.83% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PA
40.04%
nancial Snapshot Q1FY23 FY22 Growth in Revenue Growth in EBITDA Growth in PAT 29.72% 37.57% 40.04% 47.27% 68.83% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to In
47.27%
Snapshot Q1FY23 FY22 Growth in Revenue Growth in EBITDA Growth in PAT 29.72% 37.57% 40.04% 47.27% 68.83% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44
68.83%
Q1FY23 FY22 Growth in Revenue Growth in EBITDA Growth in PAT 29.72% 37.57% 40.04% 47.27% 68.83% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47
80.82%
FY22 Growth in Revenue Growth in EBITDA Growth in PAT 29.72% 37.57% 40.04% 47.27% 68.83% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47.37% 32
44.35%
7% 68.83% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47.37% 32.61% 48.32% 50.91% 37.01% 7 Financials Q1FY23 Revenue 4,982 3,497 EBIDTA 2,920
47.37%
3% 80.82% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47.37% 32.61% 48.32% 50.91% 37.01% 7 Financials Q1FY23 Revenue 4,982 3,497 EBIDTA 2,920 PAT 2
32.61%
2% 6 Key Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47.37% 32.61% 48.32% 50.91% 37.01% 7 Financials Q1FY23 Revenue 4,982 3,497 EBIDTA 2,920 PAT 2,245 EP
48.32%
ey Ratios Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47.37% 32.61% 48.32% 50.91% 37.01% 7 Financials Q1FY23 Revenue 4,982 3,497 EBIDTA 2,920 PAT 2,245 EPS 8.8
50.91%
s Q1FY23 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47.37% 32.61% 48.32% 50.91% 37.01% 7 Financials Q1FY23 Revenue 4,982 3,497 EBIDTA 2,920 PAT 2,245 EPS 8.8 2,696 N
37.01%
3 FY22 EBIT to Income EBITDA to Income PAT to Income 44.35% 47.37% 32.61% 48.32% 50.91% 37.01% 7 Financials Q1FY23 Revenue 4,982 3,497 EBIDTA 2,920 PAT 2,245 EPS 8.8 2,696 N M S E E
Advertisement